Advanced Gastric Cancer In Peripheral Blood Of Patients With Ercc1 Gene Polymorphism And Efficacy Of Oxaliplatin Chemotherapy Research

OBJECTIVE:To assess whether the polymorphism of ERCC1 Asnll8Asn (Câ†'T,rs11615)had an effect on the clinical outcome in Chinese patients treated with oxaliplatin as first-line chemotherapy regimens for advanced gastric cancer.METHODS:DNA was extracted from peripheral venous blood before chemotherapy for 71 advanced gastric cancer patients.Real-time PCR was used for genotyping.The end points considered in this research were objective tumor response(OR) and time to progression(TTP).RESULTS:Three allelotypes were found in this group,respectively their frequencies were C/C 49.29%,C/T 40.84%,T/T 9.87%.The objective tumor response rate of 47 stageâ…£cases was 51.1%..Patients with C/C genotype didn't show distinctly preponderance compared to those with C/T+T/T,between response group(CR+PR+SD) and un-response group(PD)(p=0.098).The median time to progression for 24 patients in stageâ…¢was 8 months(95%CI:6.20-9.80),patients possessing C/C genotype showed a median TTP of 8 months(95%CI:6.59-6.41),slightly differed with 7 months(95%CI:5.61-8.39) in patients with C/T+T/T genotype,but the difference was not significant(Log-rankχ~2 =2.99,P=0.083).The median time to progression for all of 71 patients was 6 months(95%CI:5.20-6.80),patients possessing C/C genotype showed a median TTP of 6 months(95%CI:5.36-6.64),significantly differed with 5 months(95%CI:3.84-5.16) in patients with C/T+T/T genotype.(Log-rankχ~2=6.04,P=0.0139).CONCLUSION:The results suggest that the ERCC1 Asn118Asn genetic polymorphisms may be associated with clinical outcomes of Chinese patients with advanced gastricl cancer accepted Oxaliplatin as first-line.but need further observation and demonstration.